Novacyt (ENXTPA:ALNOV) - Share price, News & Analysis

ALNOV fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ALNOV Stock Overview

Risk Analysis

Highly volatile share price over the past 3 months

Novacyt Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novacyt
Historical stock prices
Current Share Price	€1.78
52 Week High	€5.89
52 Week Low	€1.60
Beta	-2.93
1 Month Change	-21.13%
3 Month Change	-15.45%
1 Year Change	-55.45%
3 Year Change	1,437.93%
5 Year Change	85.83%
Change since IPO	-79.49%

Recent News & Updates

Mar 18

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

	ALNOV	FR Biotechs	FR Market
7D	-5.9%	3.6%	-1.5%
1Y	-55.4%	-39.9%	-18.8%

Return vs Industry: ALNOV underperformed the French Biotechs industry which returned -39% over the past year.

Return vs Market: ALNOV underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALNOV's price volatile compared to industry and market?
ALNOV volatility
ALNOV Average Weekly Movement	13.4%
Biotechs Industry Average Movement	8.7%
Market Average Movement	6.0%
10% most volatile stocks in FR Market	10.2%
10% least volatile stocks in FR Market	3.5%

Stable Share Price: ALNOV is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ALNOV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2006	276	David Allmond	https://www.novacyt.com

Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases.

Novacyt Fundamentals Summary

How do Novacyt's earnings and revenue compare to its market cap?
ALNOV fundamental statistics
Market Cap	UK£107.07m
Earnings (TTM)	-UK£9.73m
Revenue (TTM)	UK£95.78m

1.1x

P/S Ratio

-11.0x

P/E Ratio

Is ALNOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALNOV income statement (TTM)
Revenue	UK£95.78m
Cost of Revenue	UK£30.91m
Gross Profit	UK£64.87m
Other Expenses	UK£74.60m
Earnings	-UK£9.73m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.14
Gross Margin	67.73%
Net Profit Margin	-10.16%
Debt/Equity Ratio	0%

How did ALNOV perform over the long term?

See historical performance and comparison

Valuation

Is Novacyt undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

0.75x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: ALNOV (€1.78) is trading above our estimate of fair value (€0.01)

Significantly Below Fair Value: ALNOV is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: ALNOV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: ALNOV is unprofitable, so we can't compare its PE Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALNOV's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: ALNOV is good value based on its PB Ratio (0.8x) compared to the FR Biotechs industry average (2.6x).

Future Growth

How is Novacyt forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

48.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALNOV's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if ALNOV's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALNOV's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if ALNOV's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALNOV's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Novacyt performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

61.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALNOV is currently unprofitable.

Growing Profit Margin: ALNOV is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ALNOV is unprofitable, but has reduced losses over the past 5 years at a rate of 61.9% per year.

Accelerating Growth: Unable to compare ALNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: ALNOV has a negative Return on Equity (-6.86%), as it is currently unprofitable.

Financial Health

How is Novacyt's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: ALNOV's short term assets (£158.8M) exceed its short term liabilities (£38.9M).

Long Term Liabilities: ALNOV's short term assets (£158.8M) exceed its long term liabilities (£3.0M).

Debt to Equity History and Analysis

Debt Level: ALNOV is debt free.

Reducing Debt: ALNOV has no debt compared to 5 years ago when its debt to equity ratio was 35.3%.

Debt Coverage: ALNOV has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ALNOV has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Novacyt current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALNOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALNOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALNOV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALNOV's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALNOV has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure

CEO

David Allmond (51 yo)

0.58

Tenure

Mr. David James Allmond serves as Chief Executive Officer and Director of Novacyt S.A. since October 18, 2021. He served as Chief Business Officer of Amryt Pharma Plc until November 2021. He served as Chie...

Leadership Team

Experienced Management: ALNOV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Experienced Board: ALNOV's board of directors are considered experienced (4.9 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ALNOV insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31